HGH vs Orforglipron
FDA Approved vs Extensively Studied
monitor Mechanism-based · 50% Both HGH and Orforglipron promote fat breakdown. While additive fat loss is possible, excessive lipolysis can cause rapid free fatty acid elevation and cardiac strain. Monitor heart rate and adjust doses gradually.
Molecular Data
HGH Orforglipron
Weight 22,124 Da 882.974 Da
Half-life 3-4 hours (SC), 20-30 minutes (IV) 25-68 hours
Chain 191 amino acids Non-peptide small molecule
Type Single-chain polypeptide with two disulfide bridges Small-molecule GLP-1R agonist
Key Benefits
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
Orforglipron
01 Significant weight loss (up to 12.4% at 72 weeks)
02 Robust diabetes control (HbA1c reduction 1.3-1.6%)
03 Once-daily oral tablet format
04 No refrigeration or food restrictions required
05 Reduced cardiovascular risk markers
Dosing Protocols
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
Orforglipron
Start 3-6mg daily, titrate up to 12-36mg based on response / Once daily oral tablet
Side Effects
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
Orforglipron
Diarrhea (more prevalent than with injectable GLP-1s)
Nausea (typically improves after first month)
Appetite reduction
Contraindications
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pregnancy and breastfeeding
Research Evidence
HGH Orforglipron
Status FDA Approved Extensively Studied
References 4 studies 4 studies
Latest 2024 —
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.